Key Takeaways
- Humana reported Q1 adjusted EPS of $10.31, surpassing Wall Street’s consensus estimate of $10.19–$10.20
- Shares plunged as much as 7.4% in premarket sessions despite beating quarterly expectations
- Company maintained full-year adjusted EPS guidance at $9 while reducing reported earnings outlook to $8.36 from $8.89
- Declining Medicare Advantage Star Ratings for 2026 are pressuring bonus payments and overall profitability
- Leadership highlighted widening gap between medical expenditures and federal reimbursement rates
Humana delivered first-quarter results that exceeded analyst expectations on Wednesday, yet the market response was decidedly negative. Shares tumbled as much as 7.4% in early premarket activity after the healthcare insurer opted not to raise its annual profit projections while competitors boosted their own forecasts.
The company posted adjusted earnings of $10.31 per share, surpassing the Street’s consensus range of approximately $10.19–$10.20. Total revenue climbed to $39.65 billion from $32.11 billion in the year-ago period, also exceeding the $39.37 billion analysts had projected.
Despite these solid numbers, the positive results failed to energize investors.
Julie Utterback, an analyst at Morningstar, suggested that market participants likely anticipated an upward revision to guidance following such a robust quarterly performance. Those expectations went unfulfilled.
Humana maintained its full-year adjusted earnings forecast at a minimum of $9 per share. However, on a GAAP basis, the company actually lowered its projection to at least $8.36 per share from the earlier estimate of at least $8.89.
This downward revision accounts for expenses related to a comprehensive transformation initiative, encompassing severance packages, impairment charges, and external consulting fees.
Star Rating Decline Pressures Financial Performance
A critical factor affecting Humana’s outlook is the reduced Medicare Advantage Star Ratings scheduled for 2026. These ratings, measured on a one-to-five star system, are directly linked to government bonus payments. Diminished ratings translate to reduced bonus revenue.
Management has been communicating this challenge for multiple quarters. First-quarter net income registered at $9.83 per share, declining from $10.30 in the comparable period last year — a clear indication of this ongoing pressure.
Chief Executive Officer Jim Rechtin indicated that healthcare utilization and associated costs tracked in line with internal projections. However, he acknowledged that the disparity between the company’s medical spending and federal reimbursements has expanded year-over-year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Medical Cost Ratio Shows Positive Trend
On a more encouraging note: Humana’s insurance division benefit ratio — representing the portion of premium revenue allocated to medical expenses — registered 89.4% for the first quarter. This outperformed the company’s internal forecast of just below 90% and also beat Wall Street’s 89.7% estimate.
A lower ratio is favorable for insurers, with readings under 90% generally considered indicative of effective cost management.
Looking to the second quarter, Humana anticipates this ratio will increase to marginally above 91%, suggesting emerging cost headwinds.
The company also observed that aggregate medical and pharmacy cost trends are performing modestly better than initially projected, which Cantor analyst Sarah James identified as among the few encouraging elements in the report.
Nevertheless, James raised concerns. “HUM has several signals that the back-half of the year could be difficult to manage,” she said, calling the premarket reaction “a warning sign.”
Humana stated it will make benefit modifications as necessary to preserve stable profit margins. The federal government announced earlier this month that Medicare Advantage reimbursement rates would increase by an average of 2.48% in 2027.
Shares were recently trading down approximately 2% in premarket activity after the initial 7.4% decline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
